163 related articles for article (PubMed ID: 36604646)
1. In 'real world' patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations.
Worth H; Buhl R; Criée CP; Kardos P; Gückel E; Vogelmeier CF
Respir Res; 2023 Jan; 24(1):2. PubMed ID: 36604646
[TBL] [Abstract][Full Text] [Related]
2. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
Suissa S; Dell'Aniello S; Ernst P
Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
[TBL] [Abstract][Full Text] [Related]
4. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.
Vogelmeier CF; Worth H; Buhl R; Criée CP; Gückel E; Kardos P
Respir Res; 2022 May; 23(1):109. PubMed ID: 35501806
[TBL] [Abstract][Full Text] [Related]
5. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
[TBL] [Abstract][Full Text] [Related]
6. A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.
Miravitlles M; Verhamme K; Calverley PMA; Dreher M; Bayer V; Gardev A; de la Hoz A; Wedzicha J; Price D
Int J Chron Obstruct Pulmon Dis; 2022; 17():545-558. PubMed ID: 35309285
[TBL] [Abstract][Full Text] [Related]
7. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study.
Monteagudo M; Nuñez A; Barrecheguren M; Miravitlles M
Arch Bronconeumol; 2022 Oct; 58(10):699-707. PubMed ID: 35618580
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy
Cazzola M; Rogliani P; Calzetta L; Matera MG
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30309975
[TBL] [Abstract][Full Text] [Related]
16. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
17. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
Suissa S; Dell'Aniello S; Ernst P
COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314
[TBL] [Abstract][Full Text] [Related]
18. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
19. Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study.
Jiang L; Kendzerska T; Aaron SD; Stukel TA; Stanbrook MB; Tan W; Pequeno P; Gershon AS
COPD; 2022; 19(1):315-323. PubMed ID: 35946353
[TBL] [Abstract][Full Text] [Related]
20. Current appraisal of single inhaler triple therapy in COPD.
Lipworth B; Kuo CR; Jabbal S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
